Dominic Smethurst - Jan 31, 2025 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Role: Chief Medical Officer
Signature: /s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst
Stock symbol: CRBP
Transactions as of: Jan 31, 2025
Transactions value $: $0
Form type: 4
Date filed: 2/4/2025, 05:14 PM
Previous filing: Feb 29, 2024
Next filing: Mar 7, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRBP	Common Stock, par value $0.0001 per share	Award	$0	+27.2K	+54.4%	$0.00	77.2K	Jan 31, 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRBP	Stock options (right to buy)	Award	$0	+91.2K		$0.00	91.2K	Jan 31, 2025	Common Stock	91.2K	$9.79	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 31, 2025, the Reporting Person was granted 27,200 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 31, 2026. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
F2	This amount includes 77,200 unvested RSUs subject to each grant's vesting schedule as previously reported.
F3	The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 31, 2026, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 28, 2026.